DENAXA

Denaxa 60mg injection consists of the active ingredient Denosumab. It is a specialized medication primarily used to effectively treat osteoporosis, a medical condition characterized by progressively weakened bones. Furthermore, it is also prescribed to prevent significant bone complications in patients with certain types of cancer, such as multiple myeloma and bone metastases. Denaxa 60mg injection works by specifically inhibiting a protein called RANK ligand, which plays a crucial role in the natural breakdown of bone tissue. Studies have clearly demonstrated that it can significantly increase bone density, thereby reducing the risk of fractures in postmenopausal women suffering from osteoporosis and in patients experiencing cancer-related bone loss. For patients with moderate renal impairment, close monitoring of renal function may be necessary.

Denaxa 60mg injection should not be used in individuals with a known hypersensitivity or allergic reactions to any of its components. To ensure optimal therapeutic outcomes, adequate calcium and vitamin D supplementation is required during the course of the treatment. It is not approved for use in children and adolescents, as its safety and effectiveness in pediatric populations have not been definitively established, making its use contraindicated in individuals under 18 years of age. This medication should also be used cautiously in individuals with pre-existing hypoparathyroidism, a condition characterized by abnormally low parathyroid hormone levels.